Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells

Soybean isoflavones have been used as a potential preventive agent in anticancer research for many years. Genistein is one of the most active flavonoids in soybeans. Accumulating evidence suggests that genistein alters a variety of biological processes in estrogen-related malignancies, such as breast and prostate cancers. However, the molecular mechanism of genistein in the prevention of human colon cancer remains unclear. Here we attempted to elucidate the anticarcinogenic mechanism of genistein in human colon cancer cells. First we evaluated the growth inhibitory effect of genistein and two other isoflavones, daidzein and biochanin A, on HCT-116 and SW-480 human colon cancer cells. In addition, flow cytometry was performed to observe the morphological changes in HCT-116/SW-480 cells undergoing apoptosis or cell cycle arrest, which had been visualized using Annexin V-FITC and/or propidium iodide staining. Real-time PCR and western blot analyses were also employed to study the changes in expression of several important genes associated with cell cycle regulation. Our data showed that genistein, daidzein and biochanin A exhibited growth inhibitory effects on HCT-116/SW-480 colon cancer cells and promoted apoptosis. Genistein showed a significantly greater effect than the other two compounds, in a time- and dose-dependent manner. In addition, genistein caused cell cycle arrest in the G2/M phase, which was accompanied by activation of ATM/p53, p21waf1/cip1 and GADD45α as well as downregulation of cdc2 and cdc25A demonstrated by q-PCR and immunoblotting assay. Interestingly, genistein induced G2/M cell cycle arrest in a p53-dependent manner. These findings exemplify that isoflavones, especially genistein, could promote colon cancer cell growth inhibition and facilitate apoptosis and cell cycle arrest in the G2/M phase. The ATM/p53-p21 cross-regulatory network may play a crucial role in mediating the anticarcinogenic activities of genistein in colon cancer.

[1]  M. Velders,et al.  ERβ-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. , 2011, Carcinogenesis.

[2]  W. Qi,et al.  Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity , 2011, BMC Cancer.

[3]  A. Levine,et al.  The first 30 years of p53: growing ever more complex , 2009, Nature Reviews Cancer.

[4]  R. Levy,et al.  The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. , 2009, Nutrition reviews.

[5]  L. Saltz,et al.  Evolving treatment of advanced colon cancer. , 2009, Annual review of medicine.

[6]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[7]  Zhiwei Wang,et al.  Multi-targeted therapy of cancer by genistein. , 2008, Cancer letters.

[8]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[9]  T. Kao,et al.  Extraction yield of isoflavones from soybean cake as affected by solvent and supercritical carbon dioxide , 2008 .

[10]  J. Pouysségur,et al.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.

[11]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[12]  A. Gescher,et al.  Dietary polyphenolic phytochemicals—promising cancer chemopreventive agents in humans? A review of their clinical properties , 2007, International journal of cancer.

[13]  G. Wahl,et al.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.

[14]  G. Stark,et al.  Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors , 2006, Proceedings of the National Academy of Sciences.

[15]  P. Höglund.  DNA Damage and Tumor Surveillance: One Trigger for Two Pathways , 2006, Science's STKE.

[16]  E. Kim,et al.  Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. , 2005, Journal of medicinal food.

[17]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[18]  W. Liu,et al.  Tangutorine induces p21 expression and abnormal mitosis in human colon cancer HT-29 cells. , 2005, Biochemical pharmacology.

[19]  B. Levin,et al.  Chemoprevention of colorectal cancer: ready for routine use? , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[20]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[21]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[22]  G. Chu,et al.  Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. , 2002, DNA repair.

[23]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[24]  S. Jackson,et al.  Interfaces Between the Detection, Signaling, and Repair of DNA Damage , 2002, Science.

[25]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[26]  R. Abraham.  Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.

[27]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[28]  K. I. Kang,et al.  Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. , 2001, International journal of oncology.

[29]  P. Schär,et al.  Spontaneous DNA Damage, Genome Instability, and Cancer—When DNA Replication Escapes Control , 2001, Cell.

[30]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[31]  T. Ouchi,et al.  Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. May,et al.  Cell cycle control and cancer. , 2000, Pathologie-biologie.

[33]  G. Gordon,et al.  Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  Chong-Zhi Wang,et al.  Letter to the editor: Panaxadiol's anticancer activity is enhanced by epicatechin. , 2010, The American journal of Chinese medicine.

[35]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[36]  C. Chanchao,et al.  Trigona laeviceps propolis from Thailand: antimicrobial, antiproliferative and cytotoxic activities. , 2009, The American journal of Chinese medicine.

[37]  R. Labianca,et al.  Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  R. Doll,et al.  The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. , 1981, Journal of the National Cancer Institute.